Ioana Madalina Moșteanu

Dr. Ioana Madalina Moșteanu

Pulmonology, Institutul de Pneumoftiziologie "Marius Nasta", Bucharest, Bucureşti, Romania
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Beatrice MahlerBeatrice Mahler
Beatrice Mahler
IMIoana Madalina Moșteanu
Ioana Madalina Moșteanu
RBRaluca Bobocea
Raluca Bobocea
INIris Negoescu
Iris Negoescu
LMLeonard Florentin Mircea
Leonard Florentin Mircea
MȘMarghescu Angela Ștefania
Marghescu Angela Ștefania
A 66-year-old man, a 40-year smoker, was diagnosed with rheumatoid arthritis in 2018. He was treated for one year with methotrexate, and, later in 2020, he was diagnosed with interstitial pulmonary fibrosis. In 2022, treatment with nintedanib was initiated, with clinical improvement being indicated but without showing a functional or imaging benefit. The evolution of the disease was rapidly progressive and unfavorable, with death occurring due to pulmonary thromboembolism. Following the autopsy, triple lesions of the RA at the lung level were confirmed: interstitial, of the NSIP type with a fibrosing character at the level of the lower airways of the bilateral bronchiectasis type, and vascular damage due to pulmonary thromboembolism secondary to chronic inflammation.

15 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAlexandru Stoichita
Alexandru Stoichita
MGMaria Ghita
Maria Ghita
Beatrice MahlerBeatrice Mahler
Beatrice Mahler
SVSilviu Vlasceanu
Silviu Vlasceanu
AGAndreea Ghinet
Andreea Ghinet
AIAdriana Mihaela Iliesiu
Adriana Mihaela Iliesiu
Background: In December 2019 the World Health Organization announced that the widespread severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had become a global pandemic. The most affected organ by the novel virus is the lung, and imaging exploration of the thorax using computer tomography (CT) scanning and X-ray has had an important impact. Materials and Methods: We assessed the prevalence of lung lesions in vaccinated versus unvaccinated SARS-CoV-2 patients using an artificial intelligence (AI) platform provided by Medicai. The software analyzes the CT scans, performing the lung and lesion segmentation using a variant of the U-net convolutional network. Results: We conducted a cohort study at a tertiary lung hospital in which we included 186 patients: 107 (57.52%) male and 59 (42.47%) females, of which 157 (84.40%) were not vaccinated for SARS-CoV-2. Over five times more unvaccinated patients than vaccinated ones are admitted to the hospital and require imaging investigations. More than twice as many unvaccinated patients have more than 75% of the lungs affected. Patients in the age group 30–39 have had the most lung lesions at almost 69% of both lungs affected. Compared to vaccinated patients with comorbidities, unvaccinated patients with comorbidities had developed increased lung lesions by 5%. Conclusion: The study revealed a higher percentage of lung lesions among unvaccinated SARS-CoV-2-positive patients admitted to The National Institute of Pulmonology “Marius Nasta” in Bucharest, Romania, underlining the importance of vaccination and also the usefulness of artificial intelligence in CT interpretation.

5 April 2024 in Reports
Verified
Journal Article
Open access
PDF file
IMIoana Madalina Moșteanu
Ioana Madalina Moșteanu
Beatrice MahlerBeatrice Mahler
Beatrice Mahler
OPOana Andreea Parliteanu
Oana Andreea Parliteanu
ASAlexandru Stoichita
Alexandru Stoichita
RMRadu Matache
Radu Matache
MMMARIA MOTA
MARIA MOTA
A rise in fungal infections has been observed worldwide among patients with extended hospital stays because of the severe infection caused by the new coronavirus pandemic. A 62-year-old female patient was admitted with a severe form of Coronavirus disease 2019 (COVID-19) and spent four weeks in the intensive care unit (ICU) requiring mechanical ventilation support before being moved to a tertiary hospital for further testing. Aspergillus fumigatus filamentous fungus, Candida spp., and positive bacteriology for multidrug-resistant Klebsiella pneumoniae and Proteus mirabilis were identified by bronchial aspirate cultures. The patient’s progress was gradually encouraging while receiving oral antifungal and broad-spectrum antibiotic therapy along with respiratory physical therapy; but ultimately, thoracic surgery was necessary. Long-lasting tissue damage and severe, persistent inflammatory syndrome were the two main pathophysiological mechanisms that led to significant outcomes regarding lung lesions that were rapidly colonized by fungi and resistant flora, cardiac damage with sinus tachycardia at the slightest effort, and chronic inflammatory syndrome, which was characterized by marked asthenia, myalgias, and exercise intolerance.

25 February 2026 in Journal of Respiration
Verified
Journal Article
Open access
PDF file
ASAlexandru Stoichita
Alexandru Stoichita
Beatrice MahlerBeatrice Mahler
Beatrice Mahler
SVSilviu Vlasceanu
Silviu Vlasceanu
OPOana Andreea Parliteanu
Oana Andreea Parliteanu
ADAntonela Justina Dragomir
Antonela Justina Dragomir
AIAdriana Mihaela Iliesiu
Adriana Mihaela Iliesiu
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause persistent, multisystem complications collectively termed long COVID. Cardiovascular sequelae are among the most clinically significant yet remain incompletely characterized. This review aimed to synthesize current evidence on objective cardiovascular outcomes in long COVID and explore underlying mechanisms. Methods: A systematic review was conducted using PubMed, Scopus, and Web of Science for studies published between January 2020 and March 2024. Search terms included “COVID-19,” “long COVID,” “post-acute sequelae,” “cardiovascular,” “echocardiography,” “biomarkers,” and “imaging.” Only studies reporting at least one cardiovascular outcome, defined as either objectively measured parameters (e.g., echocardiography, cardiac biomarkers, ECG findings, or vascular function indices) or clinically relevant cardiovascular symptoms during follow-up, were included. From 412 identified records, ten recent, high-quality studies with a primary cardiovascular focus were selected. This systematic review was conducted in accordance with the PRISMA 2020 guidelines. Results: Long COVID is associated with subclinical myocardial dysfunction, arrhythmias, endothelial injury, vascular stiffness, and a prothrombotic state. Reported findings included reduced left ventricular ejection fraction, impaired global longitudinal strain, increased arterial stiffness, elevated cardiac biomarkers, new-onset hypertension, and persistent ECG changes, even in non-hospitalized patients without prior cardiovascular disease. Proposed mechanisms include myocardial inflammation, endothelial dysfunction, renin–angiotensin–aldosterone system dysregulation, autonomic imbalance, and chronic inflammation. Secondary bacterial and fungal infections were noted in critically ill survivors but did not fully explain the breadth or persistence of symptoms. Conclusions: Long COVID is a heterogeneous entity with substantial cardiovascular implications across all levels of acute disease severity. Early detection through longitudinal monitoring, standardized definitions, and multidisciplinary care is essential to reduce long-term cardiovascular risk.

1 January 2023 in Pneumologia
Verified
Journal Article
Open access
PDF file
INIris-Andreea Negoescu
Iris-Andreea Negoescu
IMIoana Madalina Moșteanu
Ioana Madalina Moșteanu
ASAnca Simionescu
Anca Simionescu
OPOana Parlițeanu
Oana Parlițeanu
AAAlina Arlet
Alina Arlet
BMBeatrice Mahler
Beatrice Mahler
Introduction: The immune response in patients with SARS-CoV2 infection is an incompletely elucidated pathophysiological challenge. There are more and more cases in which COVID-19 vaccination induces autoimmune side effects, of course, in a selected population. What are the criteria that induce such a response? How can it be prevented? These are questions that the medical world must answer. Material and Methods: A 28-year-old male patient presented with repeated small hemoptysis accompanied by pleuritic pain, which started suddenly 2 days prior. From the patient’s history, we note autoimmune thyrotoxicosis triggered by the administration of the second dose of the anti-SARS-CoV2 vaccine, but also a recent COVID-19 episode. At the time of hospitalization, slightly elevated serum values of D-dimers were noted, and the CT examination identified multiple unilateral filling defects in the middle and small right pulmonary arteries, accompanied by a ground-glass opacity suggestive of a pulmonary infarction and possible bilateral stenosis of the subclavian arteries. The extended immunological panel was negative, but genetic tests have identified two thrombophilic gene mutations. Functionally, a discrete decrease in lung volumes and a slight impairment of alveolo-capillary diffusion was observed. The clinical, imaging and functional evolution was favorable under anticoagulant treatment. Discusions: The predisposition for thrombosis in COVID-19 is determined by at least two distinct processes, subsegmental and segmental vessel occlusion and microvascular in situ immunothrombosis. Pulmonary thromboembolism occurs more frequently in the first weeks after diagnosis, but cases farther from the acute moment have also been reported in literature, including in patients with mild forms of the disease. Certain adjuvant components of the vaccines, as well as the SARS-CoV2 virus itself, can trigger autoimmune reactions in genetically predisposed individuals. Conclusion: Patients with active or recently recovered COVID-19 should be considered at an increased risk of pulmonary embolism when they present with specific symptoms, even without the existence of other risk factors.

17 July 2026 in Reports
Verified
Journal Article
Open access
PDF file
APAlexandra Paraschiv
Alexandra Paraschiv
TITeodora-Oana Iordache
Teodora-Oana Iordache
EMElena Magheran
Elena Magheran
VGVasile Grigorie
Vasile Grigorie
DDDinescu Dumitru Daniel
Dinescu Dumitru Daniel
ILIorga Ana Luiza
Iorga Ana Luiza
Background and Clinical Significance: Solitary fibrous tumors (SFTs) of the pleura are rare mesenchymal neoplasms accounting for less than 5% of pleuro-pulmonary tumors. Recurrence after complete resection of benign SFT is exceptional, with an estimated rate of approximately 3%. Case Presentation: We describe a 78-year-old woman who developed a late recurrence 10 years after resection of a giant benign pleural SFT. The new pleura-based mass was confirmed as SFT by CT-guided biopsy demonstrating spindle-cell morphology, patternless architecture, staghorn vasculature, and STAT6/CD34 positivity, consistent with intermediate-risk disease by Demicco scoring. Surgical tumorectomy was successfully performed. Conclusions: This case illustrates the unpredictable long-term behavior of pleural SFTs and reinforces the importance of extended imaging surveillance even in initially benign lesions. An updated review of contemporary classification systems, molecular mechanisms, and management strategies is included.